Great Market Potential: Important Nodes in the Domestic RSV Pharmaceutical Field
Respiratory syncytial virus (RSV) is a common enveloped RNA virus that circulates in the winter and spring. It is mainly transmitted by direct contact with the nasal secretions and respiratory droplets of infected individuals.
December 14, 2023
by Xiaoyaowan
Texas Children's Hospital announces COVID-19 vaccine requirement for workforce members
Today, Texas Children's Hospital announced it will require all members of its workforce to be vaccinated against COVID-19.
August 12, 2021
by prnewswire
FDA Fast Track designation given to mRNA RSV vaccine
Moderna’s mRNA respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, gains Fast Track designation in adults over 60 years old.
August 6, 2021
by europeanpharmaceuticalreview
Troubling Rise Seen in Both COVID-19, RSV Cases Among Children
A rise in cases of respiratory syncytial virus (RSV) is unfolding just as COVID-19 infections are increasing among children.
August 3, 2021
by drugs
Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.
July 8, 2021
by drugs
Positive topline results for nirsevimab in RSV
Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
April 27, 2021
by pharmatimes
Icosavax raises funding to advance RSV/hMPV vaccine programme
Icosavax has raised $100m through a Series B financing round to support the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine programme through initial clinical studies.
April 8, 2021
by pharmaceutical-technology
Abbott Receives EUA for PCR Assay That Detects, Differentiates SARS-CoV-2, Flu, RSV in One Test
Abbott announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) ...
March 11, 2021
by americanpharmaceuticalreview
Sanofi’s RSV treatment nirsevimab awarded PIM
Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the prevention of respiratory syncytial virus (RSV) associated lower respiratory ...
January 22, 2021
by pharmatimes
Nirsevimab gets Promising Innovative Medicine Designation from MHRA
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus (RSV) infections in healthy late preterm, term and high-risk infants.
January 19, 2021
by expresspharma
Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B, RSV Combination Test
Cepheid announced the CE-IVD marking of Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.
December 10, 2020
by americanpharmaceuticalreview
Seegene's COVID-19/FluA,B/RSV test with extraction-free feature now available in Europe
South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available in Europe.
December 3, 2020
by prnasia